Rockefeller Capital Management
VKTX icon

Rockefeller Capital Management’s Viking Therapeutics VKTX Stock Holding History

Rockefeller Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.49M Sell
38,119
-19,037
-33% -$615K ﹤0.01% 1515
2026
Q1 		$1.86M Buy
57,156
+4,103
+8% +$132K ﹤0.01% 1335
2025
Q4 		$1.87M Buy
53,053
+14,772
+39% +$523K ﹤0.01% 1273
2025
Q3 		$1.01M Sell
38,281
-28,409
-43% -$848K ﹤0.01% 1423
2025
Q2 		$1.77M Buy
66,690
+29,789
+81% +$784K ﹤0.01% 1150
2025
Q1 		$891K Buy
36,901
+13,265
+56% +$419K ﹤0.01% 1305
2024
Q4 		$951K Sell
23,636
-10,387
-31% -$592K ﹤0.01% 1268
2024
Q3 		$2.15M Buy
34,023
+17,754
+109% +$1.04M 0.01% 965
2024
Q2 		$862K Buy
+16,269
New +$1.07M ﹤0.01% 1261
2023
Q3 		– Sell
-7,527
Closed -$122K – 1819
2023
Q2 		$122K Buy
+7,527
New +$158K ﹤0.01% 1752
2023
Q1 		– Sell
-1,461
Closed -$13K – 3830
2022
Q4 		$13K Hold
1,461
– – ﹤0.01% 2979
2022
Q3 		$3K Sell
1,461
-3,500
-71% -$11.5K ﹤0.01% 3519
2022
Q2 		$14K Buy
4,961
+2,437
+97% +$6.03K ﹤0.01% 2962
2022
Q1 		$7K Hold
2,524
– – ﹤0.01% 3236
2021
Q4 		$11K Sell
2,524
-700
-22% -$3.92K ﹤0.01% 2947
2021
Q3 		$20K Buy
3,224
+500
+18% +$3.09K ﹤0.01% 2600
2021
Q2 		$16K Buy
2,724
+2,000
+276% +$11.9K ﹤0.01% 2591
2021
Q1 		$4K Buy
724
+364
+101% +$2.56K ﹤0.01% 2984
2020
Q4 		$2K Hold
360
– – ﹤0.01% 2670
2020
Q3 		$2K Buy
360
+200
+125% +$1.38K ﹤0.01% 2428
2020
Q2 		$1K Hold
160
– – ﹤0.01% 2508
2020
Q1 		$1K Buy
160
+154
+2,567% +$947 ﹤0.01% 2316
2019
Q4 		$0 Buy
+6
New +$44 ﹤0.01% 2218

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Rockefeller Capital Management's VKTX Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Viking Therapeutics (VKTX) stake by 33% in Q2 2026, selling an estimated $615K and leaving 38,119 shares worth $1.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1515.

Rockefeller Capital Management first reported a position in VKTX in Q4 2019 and has held it in 23 quarters since. The position peaked at $2.15M in Q3 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Rockefeller Capital Management held 38,119 shares of Viking Therapeutics worth $1.49M as of Q2 2026.
  • Rockefeller Capital Management sold 19,037 Viking Therapeutics shares in Q2 2026, an estimated $615K.
  • Viking Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #1515 holding.
  • Rockefeller Capital Management first reported a position in Viking Therapeutics in Q4 2019 and has held it in 23 quarters since.
  • Rockefeller Capital Management's Viking Therapeutics position peaked at $2.15M in Q3 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.